Novo Nordisk vs Eli Lilly.
Ozempiv vs Mounjaro.
We look at who is better positioned for obesity and diabetes drug demand...
Ozempiv vs Mounjaro.
We look at who is better positioned for obesity and diabetes drug demand...
Comments
A new generation of treatments on the horizon may see a shift away from injections. Investors should expect a number of mergers and acquisitions over the next few years.
https://www.thearmchairtrader.com/european-shares/novo-nordisk-eli-lilly-forecast/